IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
about
Application of IL-2 therapy to target T regulatory cell functionIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?IL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditionsChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Constitutive, but not challenge-induced, interleukin-10 production is robust in acute pre-pubescent protein and energy deficits: new support for the tolerance hypothesis of malnutrition-associated immune depression based on cytokine production in viInduction and function of virus-specific CD4+ T cell responses.Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effectsIn vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.Rapid generation of a functional NK-cell compartment.A Mouse Model of Latent Tuberculosis Infection to Study Intervention Strategies to Prevent ReactivationEnhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo.Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response.Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapyCutting edge: IL-2 immune complexes as a therapy for persistent virus infection.Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.Endoplasmic reticulum stress regulator XBP-1 contributes to effector CD8+ T cell differentiation during acute infection.Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell DynamicsMarked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant.TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis.Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection.G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responsesInterleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.
P2860
Q26827327-D802DCAC-7EA4-436E-9D9F-7007079D92C7Q28073154-F198E856-9248-4F51-B864-4FCE8130FF43Q33697777-331FD72C-6330-4FBC-9AA4-7B3E8E9B006EQ33811204-D8ECDD74-3D04-4EA7-8AF1-849F538B94BBQ34566164-47FABB91-90E5-4DD9-B085-445D8700BDE3Q34856857-773BD1EA-73BD-483B-91E5-A63291128960Q35047128-F5155959-D0C8-4100-ACF5-869B2A335563Q35144444-AF32B113-CB59-474D-85D8-C3FF729A048AQ35990718-0C244354-6356-43CD-AD9E-D12F90F616AFQ36070875-F8D53CEA-60BA-4A0C-B0B2-21B63A33FE2CQ36177023-3F81E60F-EEB0-45D4-A126-7DB39C71EE59Q36229611-1310BD94-5C1E-4858-AF6D-36F0CDA486A1Q36694460-3C8A0F06-9FBC-4926-9AF7-DAF9F3F04617Q36708311-965DC3A9-E5AA-471C-99C3-8D0406EE9333Q36948598-2A012D85-A033-452D-A4AC-9411F4BF478FQ36954938-D9A7CB30-9B4C-431A-B9D4-BBD794FD3627Q37192830-73EA12E1-535C-43E7-93B9-DF9213324748Q37251467-BBFAF74F-F0BE-4A09-BB46-287CFF672F1FQ37418550-060B789B-6980-43BC-899C-957B22DD4955Q38174602-FDEC651C-193A-4E92-8D43-10283FF524F0Q39768978-3108643C-45D8-44B9-A9BC-84432CD4D469Q40385203-B325365A-6FDB-4BEE-BB94-3A56897B2AC1Q41085383-7761527E-7E58-49AF-8F58-C04D0BEA82CAQ41956513-E117C830-15BA-4A39-A802-900CA1E51D61Q52329640-9A14B820-780F-4C71-B9EB-2ED72E70BF0B
P2860
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
@en
type
label
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
@en
prefLabel
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
@en
P2093
P1476
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
@en
P2093
Daisuke Kamimura
Eviryanti Agung
Masaaki Murakami
Masae Sato
Toshio Hirano
Yukihisa Sawa
P304
P356
10.4049/JIMMUNOL.177.1.306
P407
P577
2006-07-01T00:00:00Z